3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
8
Neoplasm Metastasis
8
Brain Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Glioma
4
Endometrial Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms by Site
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Meningioma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
abemaciclib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled